IFNA1 and lymphoma: In addition to lymphoma, notable clinical outcomes in our cohort include HES resolution with IFN-α in one subject (P5), and one treatment-related death in a patient who underwent ASCT for extremely symptomatic high-dose-OCS-dependent non-malignant disease and succumbed to infectious complications (P25).